2023 KEYNOTE INFORMATION

PLENARY KEYNOTES: EMERGING MODALITIES, PLATFORMS, AND TECHNOLOGIES -
FROM mRNA TO PROTEINS

Wednesday, March 15, 2023

PLENARY KEYNOTE PRESENTATION:
Overcoming CMC and Supply Chain Challenges for mRNA Technologies

Gregory Troiano, Chief Manufacturing Officer, mRNA Center of Excellence
Sanofi

Thanks to the rapid development of mRNA vaccines for COVID-19, the industry now has the momentum and resources to overcome many of the early CMC challenges and realize its enormous potential. This presentation will discuss the strategies in place to overcome CMC and supply chain challenges for mRNA technologies already and future innovations primed to take it to the next level.

PLENARY KEYNOTE PRESENTATION:
Affinity Proteins for Biotechnological and Medical Purposes

Sophia Hober, PhD, Professor, School of Biotechnology
KTH Royal Institute of Technology

Affinity proteins are crucial for life, for building structures, performing reactions, and for signaling purposes. In life sciences and medicine, affinity proteins are used to generate knowledge, but also for diagnostic and therapeutic purposes. This talk will cover how antibodies and small affinity molecules can be used to map the human proteome, develop diagnostic tools for in vivo visualization as well as efficiently purify therapeutics based on antibodies.

BIOGRAPHIES

Gregory Troiano, Chief Manufacturing Officer, mRNA Center of Excellence, Sanofi
Greg serves as Chief Manufacturing Officer at Translate Bio, a sanofi company, where he is responsible for strategic oversight for all aspects of cGMP CMC operations, including clinical supply, analytical testing, quality, and engineering. Prior to TBio, Greg was VP of Technology and Chief Engineer at Seer, a life sciences and health data company using nanotechnology for proteomics and biomarker discovery. Prior to Seer, Greg was VP of Nanomedicine Development and Manufacturing within Pfizer’s Pharmaceutical Sciences group, leading the development and manufacturing of novel nanoparticle drug products. Over his 20+ year career in the drug delivery field, Greg had various roles leading the pharmaceutical development of complex formulations, including numerous nano- and microparticle based systems.

Sophia Hober, PhD, Professor, School of Biotechnology, KTH Royal Institute of Technology
Sophia Hober is Professor of Molecular Biotechnology at KTH, Stockholm, Sweden. The focus of her current research group is development of predictable and robust systems for protein purification and detection by protein design and various selection methodologies. Her key scientific achievements include design and development of gene fusion systems for selective ion-exchange purification and improvements of the alkaline tolerance of protein A for industrial purification of IgG (currently a product sold by GEHealth care). Also, a novel ligand for affinity purification of proteins has been developed that display a calcium dependent binding, enabling mild elution from the column. Moreover, small bispecific protein domains with ability to strongly and selectively bind to two different proteins recently have been developed for use in diagnostic and therapeutic applications.

Track Keynote and Featured Speakers

Stream 1: Upstream

Yves Durocher, PhD, Research Officer & Head, Mammalian Cell Expression, National Research Council Canada

Stephen Goldrick, PhD, Lecturer, Digital Bioprocess Engineering, University College London, United Kingdom

Gyun Min Lee, PhD, Professor, Cell and Developmental Biology, KAIST, Korea

Daniel G. Bracewell, PhD, Professor, Bioprocess Analysis, Biochemical Engineering, University College London, United Kingdom

Stream 2: Downstream Processing

James Reilly, Associate Director, Regeneron Pharmaceuticals Inc.

Kaihui Hu He, PhD, Laboratory Head, Microbial Platform DSP, Global CMC Development, Sanofi

Richard D. Braatz, PhD, Edwin R. Gilliland Professor, Chemical Engineering, Massachusetts Institute of Technology

Lara Fernandez-Cerezo, PhD, Associate Principal Scientist, Merck

Stream 3: Gene Therapy

James Warren, PhD, Vice President, Pharmaceutical Development, Ultragenyx Pharmaceutical

Ayda S. Mayer, PhD, Executive Director, Vector Core, REGENXBIO, Inc.

Jorge F. Haller, PhD, Director, Process & Analytical Development, Prevail Therapeutics, a Wholly Owned Subsidiary of Eli Lilly and Company

Andrea C.M. Rayat, PhD, Chair & Lecturer, Biochemical Engineering, University College London

Stream 4: Cell Therapy

Vered Caplan, CEO, Orgenesis, Inc.

Michael Delahaye, Director, Team Leader Cell Therapy Bioprocessing, AstraZeneca

Florence Salmon, PhD, Vice President, Regulatory Affairs and Preclinical Development, Ridgeline Discovery

Janet Glassford, PhD, Expert Quality Assessor, MHRA

Stream 5: Analytics and Formulation

Dan Bach Kristensen, PhD, Principal Scientist, Symphogen, Denmark

Christine Carapito, PhD, Co-Head of the BioOrganic Mass Spectrometry Laboratory, CNRS Research Director, University of Strasbourg, France

Arun Alphonse Ignatius, PhD, Director, Drug Product Sciences, Macrogenics, Inc., USA

Yunus Saricay, PhD, Specialist, Research & Development, Byondis B.V., The Netherlands